$Affimed(AFMD)$ $afmd expect preliminary AFM13 data in PTCL at 2020 year-end, with more visibility on an accelerated regulatory path. Initial AFM24 data in EGFR+ solid tumors is expected in late 2020 and could provide additional upside.